Close
Help




JOURNAL

Biomarkers in Cancer

Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries

Submit a Paper


Biomarkers in Cancer 2015:Suppl. 2 19-24

Review

Published on 04 Oct 2015

DOI: 10.4137/BIC.S29329


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer

Abstract

Ameloblastoma is an odontogenic neoplasm whose molecular pathogenesis has only recently been elucidated. The discovery of recurrent activating mutations in FGFR2, BRAF, and RAS in a large majority of ameloblastomas has implicated dysregulation of MAPK pathway signaling as a critical step in the pathogenesis of this tumor. Some degree of controversy exists regarding the role of mutations affecting the sonic hedgehog (SHH) pathway, specifically Smoothened (SMO), which have been postulated to serve as either an alternative pathogenetic mechanism or secondary mutations. Here, we review recent advances in our understanding of the molecular pathogenesis of ameloblastoma as well as the diagnostic, prognostic, and therapeutic implications of these discoveries.



Downloads

PDF  (4.88 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Biomarkers in Cancer
Biomarkers in Cancer was prompt, focused and straight forward during the process. Guidance was available throughout the process. This has been one of the most enjoyable experiences in dealing with the staff of a journal publishing good quality science. It's amazing that one day you submit corrections and the next day you receive corrected proofs. And the process continues until you are completely satisfied. Amazing. The peer review process matched the standard of any international ...
Dr Faiz Nasim (Professor of Biochemistry, The Islamia University of Bahawalpur, Pakistan)
More Testimonials

Quick Links


New article and journal news notification services